Welcome to our dedicated page for Translational Development Acquisition SEC filings (Ticker: TDAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Translational Development Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Translational Development Acquisition's regulatory disclosures and financial reporting.
Translational Development Acquisition Corp. obtained shareholder approval to extend the deadline to complete a business combination by up to twelve one-month periods from June 24, 2026 to June 24, 2027. This required amendments to both its charter and its investment management trust agreement.
Each one-month extension will require a deposit into the trust account of the lesser of $200,000 and $0.03 per outstanding public share, paid two days before the extension after five days’ advance notice to the trustee. At the meeting, about 79.56% of outstanding shares were represented, and all three proposals, including the extension and trust amendments, passed with 16,621,609 votes for and 809,296 against. In connection with the extension approval, holders of 2,598,697 Class A shares elected redemption at approximately $10.70 per share, totaling about $27,817,433.95, leaving 14,651,303 Class A IPO shares outstanding.
ProLogium Holding Inc. and OPmobility signed a Memorandum of Understanding to evaluate and jointly develop solid-state battery modules and packs for electric vehicle applications. The collaboration begins with electrical performance testing of ProLogium cells under agreed protocols while OPmobility leads module design, development and manufacturing.
The release discloses ProLogium cell metrics — 900 Wh/L volumetric energy density, 380 Wh/kg gravimetric energy density, 5%→80% fast charge in ~6.4 minutes, cycle life > 1,200 cycles, and > 95% discharge performance at -20°C — and states planned ramp and mass-production milestones for the Company’s overseas facility with ramp expected between Q4 2028 and Q1 2029 and mass production and deliveries in Q2 2029. Discussions will proceed within applicable competition laws and further details are to be included in the registration/proxy materials filed in connection with the proposed business combination.
Translational Development Acquisition Corp. reported that on June 12, 2026 it converted 4,657,499 Class B ordinary shares held by its sponsor into an equal number of Class A ordinary shares. These new Class A shares carry the same restrictions that applied to the Class B shares, including transfer limits, waived redemption rights and an obligation to vote in favor of an initial business combination.
After the conversion, 21,907,499 Class A ordinary shares and one Class B ordinary share were issued and outstanding. The transaction generated no cash for the company, did not change the amount in the trust account and did not alter the per-share redemption value of the public Class A shares, which was approximately $10.69 per public share as of June 12, 2026.
Prologium Holding Inc. presents a product and commercialization overview of its superfluidized all-inorganic solid-state batteries, highlighting technology, manufacturing, patents and gigafactory plans. The presentation cites >1,100 global patents, 800,000 cells shipped to date and Taoyuan capacity of 0.5 GWh in 2025, with Dunkirk targeting commercial operations and ramp toward mass production in Q2 2029.
The deck emphasizes cell-level safety (non-flammable electrolyte, 100% ceramic separator), high ionic conductivity (57 mS/cm at 25°C) and targeted gravimetric energy density of 430–470 Wh/kg. Cost and manufacturing-efficiency claims are presented as company estimates and management projections.
Prologium Holding Inc. provided a strategic investor presentation describing its superfluidized all‑inorganic solid‑state lithium ceramic battery technology, manufacturing scale-up plans and the proposed business combination with Translational Development Acquisition Corp. (TDAC). The presentation highlights existing shipments, patent scale, planned gigafactory capacities and projected ramp milestones.
The company states it has shipped more than 800,000 cells to date, holds over 1,100 global patents (granted and pending), and describes planned production capacity at multiple sites with target commercial ramp at the Dunkirk gigafactory by Q2 2029. The communication reiterates customary forward‑looking statement cautions and notes a $250 million Minimum Cash condition tied to closing the business combination.
Translational Development Acquisition Corp. Schedule 13G discloses that Linden Advisors and Siu Min (Joe) Wong may be deemed beneficial owners of 950,000 shares of Class A Ordinary Shares as of May 27, 2026, representing approximately 5.5% of the outstanding shares. The filing states that 913,482 shares are held by Linden Capital and 36,518 shares are held by one or more Managed Accounts; Linden GP and Linden Capital are each deemed beneficial owners of the 913,482 shares (about 5.3%).
The statement lists voting and dispositive powers as shared (no sole voting or sole dispositive power reported) and provides addresses and organizational details for Linden Capital, Linden GP, Linden Advisors, and Mr. Wong.
Translational Development Acquisition Corp. director and CEO Michael B. Hoffman bought 53,395 warrants in an open-market transaction. The warrants were purchased at a weighted average price of about $0.79 per warrant, for aggregate proceeds of $42,280.50. Each warrant entitles the holder to acquire one Class A ordinary share at an exercise price of $11.50 per share. The warrants become exercisable 30 days after completion of the company’s initial business combination and expire five years after that business combination, or earlier upon redemption or liquidation. Following this transaction, Hoffman directly holds 53,395 warrants.
Translational Development Acquisition Corp. is asking shareholders to approve amendments that extend its deadline to complete a business combination from June 24, 2026, by up to twelve one‑month periods to June 24, 2027. Each extension would require a deposit into the trust account of the lesser of $200,000 or $0.03 per outstanding public share in exchange for a non‑interest bearing promissory note. Shareholders may redeem their public shares for cash in connection with these proposals, subject to a minimum net tangible asset condition of $5,000,001 and a 15% redemption cap per holder group without consent. The proxy also describes a signed Business Combination Agreement with ProLogium Holding Inc., under which Translational Development would merge into ProLogium subsidiaries, with each Class A ordinary share converting into one ProLogium Class A share and warrants becoming ProLogium warrants. Closing of the Proposed Business Combination is conditioned on multiple approvals and an Available Cash amount of at least $250,000,000; if the extension proposals fail and no deal closes within the current window, the SPAC will redeem all public shares and liquidate, leaving the warrants worthless.
Translational Development Acquisition Corp. (TDAC) entered into a Business Combination Agreement to merge with ProLogium Holding Inc., structured as a two-step merger with a recapitalization and listing of the combined company as ProLogium Technology on Nasdaq under the ticker PRLG.
The agreement implies an approximate $3.8 billion enterprise valuation on a net cash-free basis, conditions closing on customary approvals and filings, requires the combined entity to have at least $5,000,001 of net tangible assets post-closing, and conditions TDAC’s obligations on Available Cash being ≥ $250,000,000.
Translational Development Acquisition Corp. entered into a definitive Business Combination Agreement with ProLogium Holding Inc., a solid-state battery developer, implying an approximately $3.8 billion net cash-free valuation for ProLogium.
The deal uses a two-step Cayman merger structure, after a recapitalization, to make ProLogium Technology the Nasdaq-listed parent under ticker PRLG. Closing requires TDAC and ProLogium shareholder approvals, a TDAC deadline extension beyond June 24, 2026, Nasdaq listing approval, an effective Form F-4 and Available Cash of at least $250,000,000.
The agreement includes founder IP compensation capped at 2.5% of fully diluted equity, a new incentive plan reserving up to 12.5% of post-closing capital, sponsor and shareholder voting/lock-up agreements, and a registration rights agreement requiring a resale shelf within 45 days of closing. TDAC and ProLogium highlight ProLogium’s Gen4 solid-state technology, planned Dunkirk gigafactory and targeted funding from TDAC’s trust plus a common equity PIPE.